Blasts of a Different Sort
Can you tell what the diagnosis is for a man with a history of recurrent necrotizing pancreatitis and end-stage renal disease on intermittent hemodialysis by looking at his
Combining Daratumumab With Backbone Antimyeloma Agents
Dr. Raje reviews a study that compares daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone alone for the treatment of patients with multiple my
In his first President's Column, Dr. Kenneth Anderson speaks about ASH's commitment to education and to spreading awareness on important treatment advances and unprecedented scientific discoveries.
Kenneth C. Anderson, MD, highlights a recent trial about adult patients with relapsed and/or refractory Multiple Myeloma.
Lenalidomide Maintenance Therapy in Multiple MyelomaDr. Anderson has served on Celgene’s advisory board. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 366 1759 1769. McCarthy PL, Owzar
Microenvironment Induced Genomic Instability in Multiple MyelomaDr. Anderson indicated no relevant conflicts of interest. Koduru S, Wong E, Strowig T, et al. Dendritic cellmediated activation induced cytidine deaminase (AID) dependent induction of genomic instability in human myeloma. Blood. 2012 119
The Added Value of 18 F FDG PET CT in Defining Prognosis and Response in MyelomaDr. Anderson indicated no relevant conflicts of interest. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18 F FDG PET CT in
Delineating Molecular Mechanisms of Proteasome and Histone Deacetylase Inhibitor Induced Myeloma CytotoxicityDr. Anderson serves on advisory boards for Millennium and Novartis. Mannava S, Zhuang D, Nair JR et al. KLF9 is a novel transcriptional regulator of bortezomib and LBH589 induced
Combined Histone Deacetylase and Proteasome Inhibitor Therapy in MyelomaDr. Anderson indicated no relevant conflicts of interest. Harrison SJ, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple
ASCT has been a standard of care in myeloma due to achievement of both high extent and frequency of response and to the prolonged progression-free survival compared with conventional chemotherapy. However, the availability of novel therapies, including bortezomib and lenalidomide, that have improved outcome has impacted the transplant paradigm.
Can We Treat Myeloma at Early Stages?Dr. Anderson indicated no relevant conflicts of interest. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) novel biological insights and development of early treatment strategies.
Sequencing the Myeloma GenomeChapman MA, Lawrence MS, Keats JS, et al. Initial genome sequencing of multiple myeloma. Nature. 2011 471 467 472. In this study, a large multi institutional group led by investigators from the Broad Institute in Boston report
January-February 2017Volume 14, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology